Trial · NCT04219007
Vosoritide for Selected Genetic Causes of Short Stature
NCT04219007, Phase 2, Active not recruiting, Andrew Dauber
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Vosoritide for Selected Genetic Causes of Short Stature. Trials, record NCT04219007. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04219007
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Vosoritide for Selected Genetic Causes of Short Stature
- NCT number
- NCT04219007
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 56 participants, actual
- Lead sponsor
- Andrew Dauber
- Conditions
- Short Stature
- Interventions
- Vosoritide
- First posted
- 2020-01-06
- Last updated
- 2026-03-18
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Treatment Emergent Adverse Events [Safety and Tolerability] | 12 months | Number of treatment-emergent adverse events or serious adverse events per study participant |
| Primary | Incidence of Symptomatic Hypotension events [Safety and Tolerability] | 12 months | Number of symptomatic hypotension events per study participant |
| Primary | Change from Baseline in annualized growth velocity | 12 months | To evaluate the change from baseline in age-sex standardized annualized growth velocity in cm/year after 12 months of daily SC injections of vosoritide in patients with selected genetic causes of short stature. |
| Primary | Change from Baseline in standardized height SDS | 12 months | To evaluate the change from baseline in age-sex standardized height SDS after 12 months of daily SC injections of vosoritide in patients with selected genetic causes of short stature. |
| Secondary | Changes in the seated height ratio as a measure of body proportions | 12 months | To evaluate the seated height ratio (expressed as a percentage) as a measure of body proportions. Measurement after 12 months of treatment will be compared to baseline. |
| Secondary | Changes in the difference between arm span and height from baseline | 12 months | To evaluate the difference between arm span and height (measured as cm) as a measure of body proportions. Measurement after 12 months of treatment will be compared to baseline. |
| Secondary | Changes from Baseline in bone age/chronological age | 12 months | To evaluate changes from baseline in bone age/chronological age after 12 months of daily SC injections of vosoritide |
| Other | Characterize the area under the plasma concentration time-curve from time 0 to infinity (AUC0-∞) | 3 hours at each visit | Estimated by non-compartmental analysis for Day 1, 6 months, and 12 months per study participant |
| Other | Characterize the area under the plasma concentration-time curve from 0 to the time of last measurable concentration (AUC0-t) | 3 hours at each visit | Estimated by non-compartmental analysis for Day 1, 6 months, and 12 months per study participant |
| Other | Characterize maximum concentration (Cmax) of vosoritide in plasma | 3 hours at each visit | Estimated by non-compartmental analysis for Day 1, 6 months, and 12 months per study participant |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38813446 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04219007
GET https://conductscience.org/api/trials/v1/NCT04219007/registered